Literature DB >> 34593828

Neuronally-derived tau is increased in experienced breachers and is associated with neurobehavioral symptoms.

Katie A Edwards1,2, Kisha Greer1, Jacqueline Leete1, Chen Lai1, Christina Devoto1,2, Bao-Xi Qu1,2, Angela M Yarnell3, Elena Polejaeva4, Kristine C Dell5, Matthew L LoPresti6, Peter Walker7, Eric M Wassermann8, Walter Carr6,9, James R Stone10, Stephen T Ahlers11, Rany Vorn1, Carina Martin1, Jessica M Gill12,13.   

Abstract

Military and law enforcement breachers are exposed to many low-level blasts during their training and occupational experiences in which they detonate explosives to force entry into secured structures. There is a concern that exposure to these repetitive blast events in career breachers could result in cumulative neurological effects. This study aimed to determine concentrations of neurofilament light (NF-L), tau, and amyloid-beta 42 (Aβ42) in serum and in neuronal-derived extracellular vesicles (EVs) in an experienced breacher population, and to examine biomarker associations with neurobehavioral symptoms. Thirty-four participants enrolled in the study: 20 experienced breachers and 14 matched military or civilian law enforcement controls. EV tau concentrations were significantly elevated in experienced breachers (0.3301 ± 0.5225) compared to controls (-0.4279 ± 0.7557; F = 10.43, p = 0.003). No statistically significant changes were observed in EV levels of NF-L or Aβ42 or in serum levels of NF-L, tau, or Aβ42 (p's > 0.05). Elevated EV tau concentrations correlated with increased Neurobehavioral Symptom Inventory (NSI) score in experienced breachers (r = 0.596, p = 0.015) and predicted higher NSI score (F(1,14) = 7.702, p = 0.015, R2 = 0.355). These findings show that neuronal-derived EV concentrations of tau are significantly elevated and associated with neurobehavioral symptoms in this sample of experienced breachers who have a history of many low-level blast exposures.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34593828      PMCID: PMC8484560          DOI: 10.1038/s41598-021-97913-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Blast injury is a critical concern for military forces due to the use of improvised explosive devices in the Iraq and Afghanistan conflicts[1]. In contrast to large magnitude explosives in combat, experienced breachers in military and law enforcement professions encounter hundreds to thousands of training and occupational exposures to low-level blast overpressure over the course of their careers. Breachers construct and detonate explosives, often while at a close distance, to create a breach in a locked door or wall to force entry into a secured structure. While these subconcussive blast exposures do not result in medically diagnosed injuries, there may be neurological sequelae due to the chronic, repetitive nature of these exposures. Research suggests that repeated low-level blast exposure is associated with neurological effects, including cognitive, somatic, and affective symptoms as well as neurocognitive and neurosensory decline and potentially increased vulnerability to diagnosable neurological injury[2-6]. It is important to further examine the risks of developing neurological symptoms following blast exposure in this unique population as well as elucidate the underlying biological mechanisms that relate to these associated symptoms. Blood-based biomarkers are promising as potential objective indicators to identify blast exposed individuals who may be at risk for neurological symptoms and/or other deficits. In military and civilian populations, traumatic brain injuries (TBIs) have been linked to increased levels of neuronal proteins neurofilament-light (NF-L), tau, and amyloid beta-42 (Aβ42), and these increases have further been linked to symptom development[7-12]. Moreover, repeated exposure to low-level blasts has been associated with a reduction in neurocognitive performance that correlated with elevations in serum levels of NF-L, tau, and Aβ42[13]. One important issue that has been raised in TBI blood-based biomarker research is the identification of neuronal effects. Extracellular vesicles (EVs) are nanoparticles with a lipid bilayer membrane that carry proteins, genetic material, and lipids from inside of the cell, participate in cell-to-cell communication, and are readily measured in peripheral circulation[14]. EVs protect proteins from degradation and may be a stable source of brain-related proteins[15-18]. Our lab identified elevated levels of GFAP in neuronal-derived EVs of TBI patients[19], while lower serum GFAP levels were observed following blast exposure in a military training population[20]. These findings suggest that neuronal-derived EVs have a heightened specificity for central nervous system (CNS) processes, potentially increasing clinical relevance for neurological outcomes. However, the clinical relevance of serum versus neuronal-derived EV concentrations of NF-L, tau, and Aβ42 levels in experienced breacher populations remains elusive. To address this critical issue, we analyzed concentrations of NF-L, tau, and Aβ42 in serum and in neuronal-derived EVs in an experienced breacher population with a high number of low-level blast exposures and examined if these biomarkers associate with neurobehavioral symptoms.

Results

Demographics and clinical characteristics

Thirty-four males were recruited into the study (20 breachers and 14 matched military or civilian law enforcement controls). Overall blast exposures ranged from 456 to 35,800 exposures in the breacher group and from 0 to 39 exposures in the control group. The majority of participants were white (85%) military personnel (65–71%). Participants’ ages ranged from 26 to 54 years, with a mean age of 39 years. There were no statistically significant differences in demographics, prior service, Beck Depression Inventory (BDI) or Neurobehavioral Symptom Inventory (NSI) between experienced breachers and controls (Table 1). There were higher reported PCL-M scores in experienced breachers when compared with controls, indicating increased PTSD-related symptoms, although these levels do not meet clinical criteria for PTSD diagnosis.
Table 1

Demographics and clinical characteristics. Data is described using mean and SD.

Experienced breacher (N = 20)Unexposed control (N = 14)Significance
Race, no. (%)

χ2 = 2.893

p = 0.576

White17 (85)12 (85.71)
Black0 (0)1 (7.14)
Asian/Pacific Islander1 (5)1 (7.14)
American Indian/Alaskan1 (5)0 (0)
Other1 (5)0 (0)
Ethnicity (non-Hispanic), no. (%)19 (95)13 (92.86)

χ2 = 0.068

p = 0.794

Sex (male), no. (%)20 (100)14 (100)N/A
Type of service, no. (%)

χ2 = 2.839

p = 0.242

Military14 (65)10 (71.43)
Civilian law enforcement3 (20)4 (28.57)
Both3 (15)0 (0)
Age (years)
Mean age (SD)39.65 (8.337)38.86 (7.814)

t = 0.280

p = 0.781

Minimum–maximum26–5427–53
Mean years of education (SD)14.25 (1.743)14.43 (2.593)

t = -0.241

p = 0.811

Mean years of service (SD)16.80 (6.693)13.92 (6.986)

t = 1.209

p = 0.235

Number of prior blast exposures, no. (%)N/A
 < 400 (0)14 (100)
400 + 20 (100)0 (0)
Minimum–maximum456–34,8000–39
Most recent blast exposure, no. (%)

χ2 = 29.046

p < 0.01

Never0 (0)11 (78.57)
Past week4 (20)0 (0)
Past month8 (40)0 (0)
Past 6 months3 (15)0 (0)
Past year3 (15)0 (0)
More than 1 year2 (5)3 (21.43)
Mean number of self-reported head injuries (SD)0.80 (0.616)0.36 (0.497)

t = 2.228

p = 0.033

BDI (SD)4.25 (4.518)3.00 (5.038)

t = 0.757

p = 0.899

PCL-M (SD)25.55 (6.924)20.64 (4.483)

t = 2.327

p = 0.027

NSI (SD)16.90 (5.955)16.86 (5.289)

t = 0.022

p = 0.824

BDI Beck Depression Index, PCL-M Post-Traumatic Stress Disorder Checklist-Military, NSI Neurobehavioral Symptom Inventory.

Demographics and clinical characteristics. Data is described using mean and SD. χ2 = 2.893 p = 0.576 χ2 = 0.068 p = 0.794 χ2 = 2.839 p = 0.242 t = 0.280 p = 0.781 t = -0.241 p = 0.811 t = 1.209 p = 0.235 χ2 = 29.046 p < 0.01 t = 2.228 p = 0.033 t = 0.757 p = 0.899 t = 2.327 p = 0.027 t = 0.022 p = 0.824 BDI Beck Depression Index, PCL-M Post-Traumatic Stress Disorder Checklist-Military, NSI Neurobehavioral Symptom Inventory.

Protein, neuronal-derived EV, and psychometric testing

Neuronal-derived EV tau concentrations (natural log-transformed mean ± SD) were significantly elevated in experienced breachers (0.3301 ± 0.5225) compared to controls (−0.4279 ± 0.7557; F = 10.43, p = 0.003) (Fig. 1a). No statistically significant changes were noted in EV NF-L (p = 0.224) or Aβ42 (p = 0.168) (Fig. 1b,c). There were no statistically significant differences between groups in serum levels of NF-L (p = 0.672), tau (p = 0.302), or Aβ42 (p = 0.190) (Fig. 1d–f).
Figure 1

Neuronal-derived EV tau distinguishes experienced breachers from controls. (a) Exosomal tau was elevated in the experienced breacher group compared to the control group. There were no statistically significant changes in EV levels of (b) NF-L or (c) Aβ42. There were no statistically significant changes in serum levels of (d) tau, (e) NF-L, or (f) Aβ42. *indicates p < 0.05, error bars represent the mean and SD. NF-L neurofilament light, Aβ amyloid-beta.

Neuronal-derived EV tau distinguishes experienced breachers from controls. (a) Exosomal tau was elevated in the experienced breacher group compared to the control group. There were no statistically significant changes in EV levels of (b) NF-L or (c) Aβ42. There were no statistically significant changes in serum levels of (d) tau, (e) NF-L, or (f) Aβ42. *indicates p < 0.05, error bars represent the mean and SD. NF-L neurofilament light, Aβ amyloid-beta. Elevated EV tau levels significantly correlated with increased NSI score in experienced breachers (r = 0.596, p = 0.015) (Table 2). In linear regression, EV tau significantly predicted higher NSI score (F(1,14) = 7.702, p = 0.015, R = 0.355).
Table 2

Biomarker spearman correlations with psychometric tests.

Serum NF-LSerum TauSerum Aβ42EVNF-LEVTauEVAβ42
BDIPearson coefficient0.3670.0550.2810.363−0.131−0.106
p-value0.1110.8190.2290.1260.6270.665
N202020191619
PCL-MPearson coefficient0.3020.2310.2770.266−0.4960.050
p-value0.1960.3280.2370.2720.0510.840
N202020191619
NSIPearson coefficient−0.066−0.009−0.1730.1400.596*−0.310
p-value0.7830.9680.4660.5680.0150.196
N202020191619

*p < 0.01.

BDI Beck Depression Index, PCL-M Post-Traumatic Stress Disorder Checklist-Military, NSI Neurobehavioral Symptom Inventory.

Biomarker spearman correlations with psychometric tests. *p < 0.01. BDI Beck Depression Index, PCL-M Post-Traumatic Stress Disorder Checklist-Military, NSI Neurobehavioral Symptom Inventory.

Discussion

In this study we report a significant elevation in neuronal-derived EV concentrations of tau. Further, we found that this central measure of tau related to neurobehavioral symptom burden. These findings implicate neuronally-derived tau in repetitive, low-level blast exposures and suggest that this elevation relates to persistent neurological symptoms. The observation of elevated tau in neuronal-derived EVs aligns with previous reports of EV sources of tau in mild TBI, including repetitive injuries[21,22]. Conversely, our finding that experienced breachers showed no statistically significant changes in serum levels of tau, NF-L, and Aβ42 differs from prior reports of elevated levels in military and civilian TBI populations[7-12]. This discrepancy may be explained by the studied population. Evidence suggests that blast exposure has a distinct neuropathology from the blunt force impacts observed in these aforementioned studies[23]. Prior work in a blast-exposed population also reports elevated serum levels of tau, NF-L, and Aβ42[13]; however, that population was exposed acutely and earlier in their careers, during initial breacher training activities, and did not experience the cumulative exposures in this current population of experienced breachers. Many studies are showing acute effects[2,3,20], whereas ours assessed the cumulative effects over a career. The acute vs. cumulative (chronic) dimension is important, particularly if it sets the conditions for pathological conditions that take years to develop. These differing results imply not only the importance of stratifying heterogenous blunt impact and blast exposure populations (i.e. experienced breachers), but also the importance of differentiating central and peripheral neuropathological mechanisms. Tau and Aβ42 are neuronal structure proteins that can be detected in circulation after TBI with elevations linked to TBI severity and clinical outcomes[8,12]. Accumulation of these proteins has well-recognized links to neurodegenerative processes including Alzheimer’s disease and chronic traumatic encephalopathy[24-26]. Following blast exposure, evidence from preclinical models suggests marked disturbance to cerebrovascular functioning[27], although altered BBB function following blast exposures in human populations remains unclear. Because EVs transport cellular material (including neurotoxic proteins) across the BBB and may contribute to neurodegenerative processes[28], understanding the impact of neuronal-derived EVs in repetitive blast exposure is needed. Additionally, while tau is predominantly expressed in neurons, tau is not a brain-specific protein and is expressed in other tissues such as muscle fibers[29]. Thus, the ability to distinguish CNS from peripheral sources of tau is essential in the context of understanding the neurological response to repetitive blast exposures and subsequent chronic neurological outcomes; measuring tau in neuronally-derived EVs may be one avenue in which this can be accomplished. Elevated neuronal-derived EV tau correlates with increased NSI score in the breacher population, implicating neuronal-specific tau with repetitive low-level blast exposures and worse clinical outcomes. This finding suggests clinical relevance considering prior studies in military populations have also reported poor neurocognitive outcomes. Acute blast overpressure has been previously linked to decreased neurocognitive performance[2], and chronic occupational exposure to low level blasts has been linked to cognitive, affective, and physical symptoms similar to concussion[3]. Brain imaging changes together with cognitive and neurobehavioral deficits have been observed in military veterans with mTBI resulting from repetitive blast exposures[30]. Further, an over twofold increased risk in developing dementia was associated with mTBI in a large retrospective cohort study of 350,000 military personnel and veterans, highlighting an imminent concern for the aging veteran population[31,32]. The link between neurobehavioral symptoms and EV tau levels in breachers implies a combination approach of blood-based biomarkers and psychometric testing may be valuable to identify those who may be at risk for developing adverse long-term outcomes. A major strength of this study is the comparison of both serum and neuronal-derived EV levels of proteins related to neurodegeneration in a unique population with occupational exposure to repetitive low-level blasts. Importantly, we determined neuronal sources of tau were linked with neurobehavioral outcomes. The recruitment of experienced breacher and control groups with similar occupational environments controls for career-related factors (e.g. physical exertion) between groups and suggests protein changes may be more specific to repetitive blast exposures rather than other occupational factors. This study was constrained by a small sample size. The lack of additional time points precluded a longitudinal comparison of outcomes in relation to the initially reported protein levels. The biodistribution of L1-CAM should be taken into consideration in the interpretation of these findings. Although enriched in neurons[33], L1-CAM is expressed in both central and peripheral nerve cells[34], and, as described more recently, in other cell types, including blood and immune cells[35]. Examination of the mechanism causing the observed increase in neuronal-derived EV tau was also outside the scope of this work. Despite these limitations, our results suggest that examining links between neural proteins and symptoms may have clinical relevance in experienced breacher populations. Future studies should continue to investigate serum and neuronal EV levels of neuronal-related proteins to identify and verify biomarkers that may be indicative of neurological outcomes in experienced breachers.

Methods

Clinical methodology

The Institutional Review Boards at the Naval Medical Research Center (NMRC) and the National Institutes of Health (NIH) reviewed and approved all study procedures, and all methods were performed in accordance with guidelines and regulations. All participants provided written informed consent prior to study enrollment. Procedures were implemented at the NIH Clinical Center over a five-day evaluation period. The study enrolled 20 active or prior active duty military or civilian law enforcement breachers with: (1) four or more years of active breaching experience or (2) exposed to greater than 400 breaching blasts during a career but no acute exposures prior to participation in this study. Fourteen controls were enrolled with 4 or more years of military or civilian law enforcement experience, with active involvement in military or civilian law enforcement training or operations, and exposure to 40 or less blasts over their career. Exclusion criteria included: a history of moderate to severe TBI with loss of consciousness greater than 5 min, central nervous system (CNS) disorder, respiratory conditions, cardiac conditions, and any other health conditions influencing cerebral metabolism.

Demographics, clinical history, and psychometric testing

Demographic and clinical information was gathered during interviews with participants. Psychometric tests were utilized to evaluate cognitive domains and symptomology. The Beck Depression Inventory (BDI) was used to measure depression symptom severity[36]. The BDI is a 21-item self-report rating scale with high internal consistency for both psychiatric and non-psychiatric populations (α = 0.86 and 0.81, respectively)[37]. The Post-Traumatic Stress Disorder Checklist-Military (PCL-M) was administered to screen for combat-related PTSD symptoms. The PCL-M is a 17-item self-report scale. It has been shown to have high test–retest reliability (r = 0.96) and internal consistency (α = 0.96) in Vietnam veterans[38]. The Neurobehavioral Symptom Inventory (NSI) was used to assess postconcussive symptoms. The NSI is a 22-item self-report scale and has shown both excellent internal consistency (α = 0.95) as well as the ability to differentiate veterans with TBIs from those without[39].

Blood biomarkers

Non-fasting blood samples were collected between 9:00am and 12:00 pm prior to interviews and the psychometric testing. Peripheral blood samples were drawn into ethylenediaminetetraacetic acid (EDTA) tubes and processed for serum within one hour using standard protocols[11]. Blood samples were stored at −80 °C until batch assay processing.

Neuronal-derived EV isolation

Total EVs were isolated from frozen serum aliquots and enriched for neuronal-derived EVs as previously described[22]. Briefly, EVs were isolated from 0.5 mL of frozen human serum following ExoQuick manufacturer instructions (System Biosciences, Cat # EXOQ5TM-1, Palo Alto, CA, USA) and MISEV2018 reporting guidelines[40] as previously described[41]. For EV characterization data, see supplementary material and supplemental fig. S1. Neuronal-derived EVs were enriched by using 4 μg of biotinylated antibodies against neuronal surface markers CD171 (L1CAM) (clone 5G3; eBioscience, San Diego, CA, USA) in 50 μL of 3% Bovine Serum Albumin (BSA) (Thermo-Fisher Scientific Inc., Rockford, IL, USA), and followed by adding 15 μL of Streptavidin-agarose Ultralink resin (Thermo-Fisher Scientific Inc., Rockford, IL, USA) in 25 μL of 3% BSA per tube. The resin pellet was resuspended in 200 μL of 0.1 M glycine–HCl and centrifuged at 4 °C (for 10 min at 4500 × g). Supernatant fluid was then harvested to new collecting tubes containing 25 μL of 10% BSA and 15 μL of 1 M Tris–HCl and mixed. Neuronal-derived EVs were lysed with equal volume of mammalian protein extraction reagent (M-PER) (Thermo-Fisher Scientific Inc., Rockford, IL, USA), and then the lysis was ready for downstream analysis.

Protein quantification

NFL, tau, and Aβ42 proteomic analyses were measured separately from serum samples and neuronal-derived EVs in duplicate using high-definition (HD-1), single-molecule array technology (Simoa, Quanterix, Lexington, MA). The coefficient of variation for all concentration values were < 20%. The lower limit of detection for each assay are: NFL, 0.038 pg/mL; tau, 0.019 pg/mL; and Aβ42, 0.045 pg/mL.

Statistical analysis

Statistical analysis was conducted with SPSS Build 1.0.0.1298 (Armonk, NY: IBM Corp.). Figures were created using GraphPad Prism version 8.2.0 (La Jolla, CA: GraphPad Software). Demographic and clinical characteristics were compared between the experienced breacher and control groups using chi-square and independent samples t-test. To compare biomarker levels between the experienced breacher and control groups, values were natural log-transformed to adjust for normality. Pearson’s correlations were used to evaluate biomarker values and psychometric tests within the breacher group. Protein concentrations were compared between groups using one-way ANOVA. Linear regression was subsequently run to determine ability of significant biomarkers to predict psychometric testing outcomes within the experienced breacher group. Statistical tests were two-tailed and p < 0.05 was considered a significant difference. Supplementary Information.
  39 in total

1.  Tau is widely expressed in rat tissues.

Authors:  Y Gu; F Oyama; Y Ihara
Journal:  J Neurochem       Date:  1996-09       Impact factor: 5.372

2.  Risk of dementia after TBI - a cause of growing concern.

Authors:  Cassandra L Pattinson; Jessica M Gill
Journal:  Nat Rev Neurol       Date:  2018-09       Impact factor: 42.937

Review 3.  Exosome platform for diagnosis and monitoring of traumatic brain injury.

Authors:  Douglas D Taylor; Cicek Gercel-Taylor
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-09-26       Impact factor: 6.237

Review 4.  Exosomes in Acquired Neurological Disorders: New Insights into Pathophysiology and Treatment.

Authors:  Nicole Osier; Vida Motamedi; Katie Edwards; Ava Puccio; Ramon Diaz-Arrastia; Kimbra Kenney; Jessica Gill
Journal:  Mol Neurobiol       Date:  2018-04-16       Impact factor: 5.590

5.  Higher exosomal tau, amyloid-beta 42 and IL-10 are associated with mild TBIs and chronic symptoms in military personnel.

Authors:  Jessica Gill; Maja Mustapic; Ramon Diaz-Arrastia; Rael Lange; Seema Gulyani; Tom Diehl; Vida Motamedi; Nicole Osier; Robert A Stern; Dimitrios Kapogiannis
Journal:  Brain Inj       Date:  2018-06-18       Impact factor: 2.311

6.  Modeling the Long-Term Consequences of Repeated Blast-Induced Mild Traumatic Brain Injuries.

Authors:  Denes V Agoston
Journal:  J Neurotrauma       Date:  2017-09       Impact factor: 5.269

7.  Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin.

Authors:  M Moos; R Tacke; H Scherer; D Teplow; K Früh; M Schachner
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

8.  Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation.

Authors:  William A Banks; Priyanka Sharma; Kristin M Bullock; Kim M Hansen; Nils Ludwig; Theresa L Whiteside
Journal:  Int J Mol Sci       Date:  2020-06-21       Impact factor: 5.923

9.  Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.

Authors:  Clotilde Théry; Kenneth W Witwer; Elena Aikawa; Maria Jose Alcaraz; Johnathon D Anderson; Ramaroson Andriantsitohaina; Anna Antoniou; Tanina Arab; Fabienne Archer; Georgia K Atkin-Smith; D Craig Ayre; Jean-Marie Bach; Daniel Bachurski; Hossein Baharvand; Leonora Balaj; Shawn Baldacchino; Natalie N Bauer; Amy A Baxter; Mary Bebawy; Carla Beckham; Apolonija Bedina Zavec; Abderrahim Benmoussa; Anna C Berardi; Paolo Bergese; Ewa Bielska; Cherie Blenkiron; Sylwia Bobis-Wozowicz; Eric Boilard; Wilfrid Boireau; Antonella Bongiovanni; Francesc E Borràs; Steffi Bosch; Chantal M Boulanger; Xandra Breakefield; Andrew M Breglio; Meadhbh Á Brennan; David R Brigstock; Alain Brisson; Marike Ld Broekman; Jacqueline F Bromberg; Paulina Bryl-Górecka; Shilpa Buch; Amy H Buck; Dylan Burger; Sara Busatto; Dominik Buschmann; Benedetta Bussolati; Edit I Buzás; James Bryan Byrd; Giovanni Camussi; David Rf Carter; Sarah Caruso; Lawrence W Chamley; Yu-Ting Chang; Chihchen Chen; Shuai Chen; Lesley Cheng; Andrew R Chin; Aled Clayton; Stefano P Clerici; Alex Cocks; Emanuele Cocucci; Robert J Coffey; Anabela Cordeiro-da-Silva; Yvonne Couch; Frank Aw Coumans; Beth Coyle; Rossella Crescitelli; Miria Ferreira Criado; Crislyn D'Souza-Schorey; Saumya Das; Amrita Datta Chaudhuri; Paola de Candia; Eliezer F De Santana; Olivier De Wever; Hernando A Del Portillo; Tanguy Demaret; Sarah Deville; Andrew Devitt; Bert Dhondt; Dolores Di Vizio; Lothar C Dieterich; Vincenza Dolo; Ana Paula Dominguez Rubio; Massimo Dominici; Mauricio R Dourado; Tom Ap Driedonks; Filipe V Duarte; Heather M Duncan; Ramon M Eichenberger; Karin Ekström; Samir El Andaloussi; Celine Elie-Caille; Uta Erdbrügger; Juan M Falcón-Pérez; Farah Fatima; Jason E Fish; Miguel Flores-Bellver; András Försönits; Annie Frelet-Barrand; Fabia Fricke; Gregor Fuhrmann; Susanne Gabrielsson; Ana Gámez-Valero; Chris Gardiner; Kathrin Gärtner; Raphael Gaudin; Yong Song Gho; Bernd Giebel; Caroline Gilbert; Mario Gimona; Ilaria Giusti; Deborah Ci Goberdhan; André Görgens; Sharon M Gorski; David W Greening; Julia Christina Gross; Alice Gualerzi; Gopal N Gupta; Dakota Gustafson; Aase Handberg; Reka A Haraszti; Paul Harrison; Hargita Hegyesi; An Hendrix; Andrew F Hill; Fred H Hochberg; Karl F Hoffmann; Beth Holder; Harry Holthofer; Baharak Hosseinkhani; Guoku Hu; Yiyao Huang; Veronica Huber; Stuart Hunt; Ahmed Gamal-Eldin Ibrahim; Tsuneya Ikezu; Jameel M Inal; Mustafa Isin; Alena Ivanova; Hannah K Jackson; Soren Jacobsen; Steven M Jay; Muthuvel Jayachandran; Guido Jenster; Lanzhou Jiang; Suzanne M Johnson; Jennifer C Jones; Ambrose Jong; Tijana Jovanovic-Talisman; Stephanie Jung; Raghu Kalluri; Shin-Ichi Kano; Sukhbir Kaur; Yumi Kawamura; Evan T Keller; Delaram Khamari; Elena Khomyakova; Anastasia Khvorova; Peter Kierulf; Kwang Pyo Kim; Thomas Kislinger; Mikael Klingeborn; David J Klinke; Miroslaw Kornek; Maja M Kosanović; Árpád Ferenc Kovács; Eva-Maria Krämer-Albers; Susanne Krasemann; Mirja Krause; Igor V Kurochkin; Gina D Kusuma; Sören Kuypers; Saara Laitinen; Scott M Langevin; Lucia R Languino; Joanne Lannigan; Cecilia Lässer; Louise C Laurent; Gregory Lavieu; Elisa Lázaro-Ibáñez; Soazig Le Lay; Myung-Shin Lee; Yi Xin Fiona Lee; Debora S Lemos; Metka Lenassi; Aleksandra Leszczynska; Isaac Ts Li; Ke Liao; Sten F Libregts; Erzsebet Ligeti; Rebecca Lim; Sai Kiang Lim; Aija Linē; Karen Linnemannstöns; Alicia Llorente; Catherine A Lombard; Magdalena J Lorenowicz; Ákos M Lörincz; Jan Lötvall; Jason Lovett; Michelle C Lowry; Xavier Loyer; Quan Lu; Barbara Lukomska; Taral R Lunavat; Sybren Ln Maas; Harmeet Malhi; Antonio Marcilla; Jacopo Mariani; Javier Mariscal; Elena S Martens-Uzunova; Lorena Martin-Jaular; M Carmen Martinez; Vilma Regina Martins; Mathilde Mathieu; Suresh Mathivanan; Marco Maugeri; Lynda K McGinnis; Mark J McVey; David G Meckes; Katie L Meehan; Inge Mertens; Valentina R Minciacchi; Andreas Möller; Malene Møller Jørgensen; Aizea Morales-Kastresana; Jess Morhayim; François Mullier; Maurizio Muraca; Luca Musante; Veronika Mussack; Dillon C Muth; Kathryn H Myburgh; Tanbir Najrana; Muhammad Nawaz; Irina Nazarenko; Peter Nejsum; Christian Neri; Tommaso Neri; Rienk Nieuwland; Leonardo Nimrichter; John P Nolan; Esther Nm Nolte-'t Hoen; Nicole Noren Hooten; Lorraine O'Driscoll; Tina O'Grady; Ana O'Loghlen; Takahiro Ochiya; Martin Olivier; Alberto Ortiz; Luis A Ortiz; Xabier Osteikoetxea; Ole Østergaard; Matias Ostrowski; Jaesung Park; D Michiel Pegtel; Hector Peinado; Francesca Perut; Michael W Pfaffl; Donald G Phinney; Bartijn Ch Pieters; Ryan C Pink; David S Pisetsky; Elke Pogge von Strandmann; Iva Polakovicova; Ivan Kh Poon; Bonita H Powell; Ilaria Prada; Lynn Pulliam; Peter Quesenberry; Annalisa Radeghieri; Robert L Raffai; Stefania Raimondo; Janusz Rak; Marcel I Ramirez; Graça Raposo; Morsi S Rayyan; Neta Regev-Rudzki; Franz L Ricklefs; Paul D Robbins; David D Roberts; Silvia C Rodrigues; Eva Rohde; Sophie Rome; Kasper Ma Rouschop; Aurelia Rughetti; Ashley E Russell; Paula Saá; Susmita Sahoo; Edison Salas-Huenuleo; Catherine Sánchez; Julie A Saugstad; Meike J Saul; Raymond M Schiffelers; Raphael Schneider; Tine Hiorth Schøyen; Aaron Scott; Eriomina Shahaj; Shivani Sharma; Olga Shatnyeva; Faezeh Shekari; Ganesh Vilas Shelke; Ashok K Shetty; Kiyotaka Shiba; Pia R-M Siljander; Andreia M Silva; Agata Skowronek; Orman L Snyder; Rodrigo Pedro Soares; Barbara W Sódar; Carolina Soekmadji; Javier Sotillo; Philip D Stahl; Willem Stoorvogel; Shannon L Stott; Erwin F Strasser; Simon Swift; Hidetoshi Tahara; Muneesh Tewari; Kate Timms; Swasti Tiwari; Rochelle Tixeira; Mercedes Tkach; Wei Seong Toh; Richard Tomasini; Ana Claudia Torrecilhas; Juan Pablo Tosar; Vasilis Toxavidis; Lorena Urbanelli; Pieter Vader; Bas Wm van Balkom; Susanne G van der Grein; Jan Van Deun; Martijn Jc van Herwijnen; Kendall Van Keuren-Jensen; Guillaume van Niel; Martin E van Royen; Andre J van Wijnen; M Helena Vasconcelos; Ivan J Vechetti; Tiago D Veit; Laura J Vella; Émilie Velot; Frederik J Verweij; Beate Vestad; Jose L Viñas; Tamás Visnovitz; Krisztina V Vukman; Jessica Wahlgren; Dionysios C Watson; Marca Hm Wauben; Alissa Weaver; Jason P Webber; Viktoria Weber; Ann M Wehman; Daniel J Weiss; Joshua A Welsh; Sebastian Wendt; Asa M Wheelock; Zoltán Wiener; Leonie Witte; Joy Wolfram; Angeliki Xagorari; Patricia Xander; Jing Xu; Xiaomei Yan; María Yáñez-Mó; Hang Yin; Yuana Yuana; Valentina Zappulli; Jana Zarubova; Vytautas Žėkas; Jian-Ye Zhang; Zezhou Zhao; Lei Zheng; Alexander R Zheutlin; Antje M Zickler; Pascale Zimmermann; Angela M Zivkovic; Davide Zocco; Ewa K Zuba-Surma
Journal:  J Extracell Vesicles       Date:  2018-11-23

Review 10.  Extracellular Vesicle-Mediated Cell⁻Cell Communication in the Nervous System: Focus on Neurological Diseases.

Authors:  Celeste Caruso Bavisotto; Federica Scalia; Antonella Marino Gammazza; Daniela Carlisi; Fabio Bucchieri; Everly Conway de Macario; Alberto J L Macario; Francesco Cappello; Claudia Campanella
Journal:  Int J Mol Sci       Date:  2019-01-20       Impact factor: 5.923

View more
  4 in total

1.  Elevations in Tumor Necrosis Factor Alpha and Interleukin 6 From Neuronal-Derived Extracellular Vesicles in Repeated Low-Level Blast Exposed Personnel.

Authors:  Katie A Edwards; Jacqueline J Leete; Ethan G Smith; Alycia Quick; Claire M Modica; Eric M Wassermann; Elena Polejaeva; Kristine C Dell; Matthew LoPresti; Peter Walker; Meghan O'Brien; Chen Lai; Bao-Xi Qu; Christina Devoto; Walter Carr; James R Stone; Stephen T Ahlers; Jessica M Gill
Journal:  Front Neurol       Date:  2022-04-21       Impact factor: 4.003

2.  Elevated Axonal Protein Markers Following Repetitive Blast Exposure in Military Personnel.

Authors:  Rany Vorn; Rosanne Naunheim; Chen Lai; Chelsea Wagner; Jessica M Gill
Journal:  Front Neurosci       Date:  2022-04-29       Impact factor: 4.677

3.  A Pilot Study of Whole-Blood Transcriptomic Analysis to Identify Genes Associated with Repetitive Low-Level Blast Exposure in Career Breachers.

Authors:  Rany Vorn; Katie A Edwards; James Hentig; Sijung Yun; Hyung-Suk Kim; Chen Lai; Christina Devoto; Angela M Yarnell; Elena Polejaeva; Kristine C Dell; Matthew L LoPresti; Peter Walker; Walter Carr; James R Stone; Stephen T Ahlers; Jessica M Gill
Journal:  Biomedicines       Date:  2022-03-17

Review 4.  Post-Concussion Syndrome and Chronic Traumatic Encephalopathy: Narrative Review on the Neuropathology, Neuroimaging and Fluid Biomarkers.

Authors:  Ioannis Mavroudis; Dimitrios Kazis; Rumana Chowdhury; Foivos Petridis; Vasiliki Costa; Ioana-Miruna Balmus; Alin Ciobica; Alina-Costina Luca; Iulian Radu; Romeo Petru Dobrin; Stavros Baloyannis
Journal:  Diagnostics (Basel)       Date:  2022-03-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.